

Avishield ND B1, Lyophilisate for Oculonasal Suspension/Use in Drinking Water for Chickens

Authorised

- Newcastle disease virus, strain B1 Hitchner, Live

Product identification

Medicine name:

Avishield ND B1, Lyophilisate for Oculonasal Suspension/Use in Drinking Water for Chickens

Active substance:

Newcastle disease virus, strain B1 Hitchner, Live

Target species:

Chicken

Route of administration:

Oculonasal use
Oral use

Product details

Active substance and strength:

Newcastle disease virus, strain B1 Hitchner, Live
6.00 log₁₀ 50% tissue culture infectious dose / 1.00 Dose

Pharmaceutical form:

Lyophilisate for ocular nasal suspension/use in drinking water

Withdrawal period by route of administration:**Ocular nasal use:**

-

Chicken

- Meat and offal. 0 day

Oral use:

-

Chicken

- Meat and offal. 0 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI01AD06

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

United Kingdom (Northern Ireland)

Package description:

Carton with 10 vials of 2500 doses of vaccine. Colourless glass vials (type I), which are closed with brombutyl rubber stoppers and sealed with aluminium caps.

Carton with 10 vials of 5000 doses of vaccine. Colourless glass vials (type I), which are closed with brombutyl rubber stoppers and sealed with aluminium caps.

Carton with 10 vials of 1000 doses of vaccine. Colourless glass vials (type I), which are closed with brombutyl rubber stoppers and sealed with aluminium caps.

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Izo S.r.l.

Marketing authorisation date:

29/03/2018

Manufacturing sites for batch release:

Genera d.d.

Responsible authority:

The Veterinary Medicines Directorate

Authorisation number:

Vm 61812/3001

Date of authorisation status change:

18/04/2023

Reference member state:

Netherlands

Procedure number:

NL/V/0293/001

Concerned member states:

Austria Belgium Croatia Czechia Denmark Estonia France Germany Greece
Hungary Ireland Italy Latvia Lithuania Poland Portugal Romania Slovakia
Slovenia Spain United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Combined File of all Documents